{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:38:00Z","timestamp":1760384280515},"reference-count":42,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.jad.2004.05.008","type":"journal-article","created":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T13:05:21Z","timestamp":1092834321000},"page":"263-275","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder"],"prefix":"10.1016","volume":"83","author":[{"given":"Robert","family":"Lasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Bossie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Gharabawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marielle","family":"Eerdekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry A.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2004.05.008_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0193-953X(02)00085-0","article-title":"Boundaries of schizophrenia","volume":"26","author":"Adler","year":"2003","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.jad.2004.05.008_bib2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib3","series-title":"DSM-IV: Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"1994"},{"key":"10.1016\/j.jad.2004.05.008_bib4","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"APA","year":"2002","journal-title":"Am. J. Psych."},{"key":"10.1016\/j.jad.2004.05.008_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0447.1994.tb05828.x","article-title":"Subjective response to neuroleptics and the quality of life: implications for treatment outcome","volume":"380","author":"Awad","year":"1994","journal-title":"Acta Psychiatr. Scand., Suppl."},{"key":"10.1016\/j.jad.2004.05.008_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1034\/j.1399-5618.2002.40103.x","article-title":"The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania","volume":"4","author":"Baker","year":"2002","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2004.05.008_bib7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4088\/JCP.v62n1104","article-title":"Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?","volume":"62","author":"Bloch","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib8","article-title":"Long-acting risperidone reduces symptoms of depression and anxiety in patients with schizophrenia and schizoaffective disorder","author":"Canuso","year":"2003"},{"key":"10.1016\/j.jad.2004.05.008_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1399-5618.2003.02237.x","article-title":"Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania","volume":"5","author":"Chengappa","year":"2003","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2004.05.008_bib10","first-page":"233","article-title":"Extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.jad.2004.05.008_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib12","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"Consensus","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jad.2004.05.008_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2004.05.008_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1192\/bjp.146.5.469","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial: II. The incidence of compliance problems, side-effects, neurotic symptoms and depression","volume":"146","author":"Curson","year":"1985","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0447.1990.tb05283.x","article-title":"Pharmacokinetics of antipsychotic drugs in man","volume":"358","author":"Dahl","year":"1990","journal-title":"Acta Psychiatr. Scand., Suppl."},{"key":"10.1016\/j.jad.2004.05.008_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","article-title":"Depot antipsychotic drugs. Place in therapy","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.jad.2004.05.008_bib17","series-title":"ACNP Scientific abstracts, ACNP 41st Annual Meeting, December 8\u201312, 2002, San Juan, Puerto Rico","first-page":"179","article-title":"Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome","author":"Docherty","year":"2002"},{"key":"10.1016\/j.jad.2004.05.008_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1176\/appi.ajp.159.1.103","article-title":"Antipsychotic medication adherence: is there a difference between typical and atypical agents?","volume":"159","author":"Dolder","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib19","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"DSM","year":"1994"},{"key":"10.1016\/j.jad.2004.05.008_bib20","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12 month evaluation of the first long-acting 2nd generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1176\/appi.ps.53.1.94","article-title":"Pharmacologic treatment of hospitalized patients with schizoaffective disorder","volume":"53","author":"Flynn","year":"2002","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2004.05.008_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0920-9964(01)00210-9","article-title":"Neuroanatomic characterization of schizoaffective disorder using MRI: a pilot study","volume":"55","author":"Getz","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2004.05.008_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotics","volume":"160","author":"Kane","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2004.05.008_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002130050755","article-title":"Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial","volume":"140","author":"Keck","year":"1998","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jad.2004.05.008_bib26","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0165-0327(00)00177-4","article-title":"A review of randomized, controlled clinical trials in acute mania","volume":"59","author":"Keck","year":"2000","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2004.05.008_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-200102000-00007","article-title":"Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies","volume":"21","author":"Keck","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2004.05.008_bib28","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1176\/ajp.156.8.1138","article-title":"Treatment of schizoaffective disorder and schizophrenia with mood symptoms","volume":"156","author":"Levinson","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib29","article-title":"Risperidone vs. conventional antipsychotics: a prospective randomized naturalistic effectiveness trial of outcomes in chronic schizophrenia","author":"Mahmoud","year":"1997"},{"key":"10.1016\/j.jad.2004.05.008_bib30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/070674370104600308","article-title":"Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities","volume":"46","author":"Mcintyre","year":"2001","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0924-9338(02)00645-4","article-title":"Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder","volume":"17","author":"Novak-Grubic","year":"2002","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.jad.2004.05.008_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004850-200015060-00005","article-title":"Effects of risperidone on affective symptoms in patients with schizophrenia","volume":"15","author":"Peuskens","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2004.05.008_bib34","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety","volume":"159","author":"Sachs","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib35","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial","volume":"21","author":"Segal","year":"1998","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2004.05.008_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1176\/appi.ajp.160.7.1263","article-title":"Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study","volume":"160","author":"Tohen","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.174.1.15","article-title":"Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy","volume":"174","author":"Tran","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib39","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00005650-200208000-00002","article-title":"Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission","volume":"40","author":"Valenstein","year":"2002","journal-title":"Med. Care"},{"key":"10.1016\/j.jad.2004.05.008_bib40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4088\/JCP.v62n1011","article-title":"Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study","volume":"62","author":"Vieta","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4088\/JCP.v62n0809","article-title":"Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD)","volume":"62","author":"Vieta","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2004.05.008_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilizers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial","volume":"182","author":"Yatham","year":"2003","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032704001867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032704001867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T06:07:03Z","timestamp":1682748423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032704001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":42,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0165032704001867"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2004.05.008","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}